Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

1.180 +0.030 (+2.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Avrobio Inc

< Previous 1 2 3 Next >
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program... 
Via Benzinga
Dow Tumbles 100 Points; Micron Technology Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping over 100 points on Monday. The Dow traded down 0.36% to 33,306.30 while the NASDAQ rose 0.39% to 12,707.21. The S&P 500,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
  
Via Benzinga
Nasdaq Rises Over 50 Points; Greenhill Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded down 0.20% to 33,359.71 while the NASDAQ rose 0.47% to 12,717.37. The S&P... 
Via Benzinga
Recap: Avrobio Q1 Earnings
 
Via Benzinga
Avrobio Touts New Positive Data From Gaucher Disease Gene Therapy
 
Via Benzinga
Recap: Avrobio Q2 Earnings
  Avrobio (NASDAQ:AVRO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS). 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study
 
Via Benzinga
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
 
Via Benzinga
Avrobio: Q1 Earnings Insights
Avrobio (NASDAQ:AVRO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpoints
Avrobio Inc (NASDAQ: AVRO) shares are trading higher after the company announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months
Avrobio Inc (NASDAQ: AVRO) announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Recap: Avrobio Q4 Earnings
Avrobio (NASDAQ:AVRO) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
AVROBIO Announces Clinical Data For Gaucher Disease Gene Therapy; Says 'Following positive feedback from FDA and MHRA, registrational, global Phase 2/3 clinical trial for GD3 planned for second half 2023'
New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3... 
Via Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Nanobiotix (NASDAQ:NBTX) shares rose 16.4% to $2.7 during Friday's after-market session. The company's market cap stands at $94.1 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
AVROBIO Shares Climb As FDA Grants Orphan Drug Status To Genetic Disorder Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for AVROBIO’s (NASDAQ: AVRO) lead drug AVR-RD-05 for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.